{"id":"NCT01973387","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma","officialTitle":"A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-28","primaryCompletion":"2015-12-01","completion":"2017-08-11","firstPosted":"2013-10-31","resultsPosted":"2017-02-23","lastUpdate":"2018-07-24"},"enrollment":160,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":[]},{"type":"DRUG","name":"Ibrutinib","otherNames":[]}],"arms":[{"label":"Treatment Arm A","type":"EXPERIMENTAL"},{"label":"Treatment Arm B","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"From the date of randomization to the date of disease progression or death, whichever was first reported (Up to 3.7 years)","effectByArm":[{"arm":"Ibrutinib","deltaMin":null,"sd":null},{"arm":"Rituximab","deltaMin":8.38,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":26,"countries":["Australia","China","Malaysia","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":104},"commonTop":["Neutrophil Count Decreased","Platelet Count Decreased","Diarrhoea","Pyrexia","Neutropenia"]}}